Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics, Safety and Efficacy of ARRY-371797 [ARRY-797] in Patients With Rheumatoid Arthritis (RA) Receiving Stable Doses of Methotrexate (MTX).

Next Previous
Trial Profile

A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics, Safety and Efficacy of ARRY-371797 [ARRY-797] in Patients With Rheumatoid Arthritis (RA) Receiving Stable Doses of Methotrexate (MTX).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emprumapimod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Sponsors Array BioPharma

Most Recent Events

  • 09 Jul 2009 Results reported in a Array BioPharma media release.
  • 01 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
  • 01 May 2009 Actual number of patients (28) added as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top